These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38054958)

  • 21. New Onset of Tuberculosis Complicating FDG PET/CT Evaluation in Patient With Recent Chimeric Antigen Receptor T-Cell Therapy.
    Wang G; Yang X; Wang H; Wang W; Yang J
    Clin Nucl Med; 2023 Jul; 48(7):647-649. PubMed ID: 37083630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy.
    Holland EM; Yates B; Ling A; Yuan CM; Wang HW; Stetler-Stevenson M; LaLoggia M; Molina JC; Lichtenstein DA; Lee DW; Ligon JA; Shalabi H; Ahlman MA; Shah NN
    Blood Adv; 2022 Apr; 6(7):2167-2182. PubMed ID: 34920453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
    Jiménez-Ubieto A; Martín-Muñoz A; Poza M; Dorado S; García-Ortiz A; Revilla E; Sarandeses P; Ruiz-Heredia Y; Baumann T; Rodríguez A; Calbacho M; Sánchez PM; Pina JMS; García-Sancho AM; Figaredo G; Rufián L; Rodríguez M; Carneros L; Martínez-Laperche C; Bastos-Oreiro M; Wang C; Cedena MT; Rapado I; de Toledo P; Gallardo M; Valeri A; Ayala R; Martínez-López J; Barrio S
    Front Immunol; 2023; 14():1188818. PubMed ID: 37342332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL).
    Wielenberg CF; Fostitsch JC; Volz C; Marks R; Michalski K; Wäsch R; Zeiser R; Ruf J; Meyer PT; Klein C
    Nuklearmedizin; 2024 Aug; 63(4):252-258. PubMed ID: 38593856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of FDG-PET/CT response for patient selection before chimeric antigen receptor-T-cells therapy in non-Hodgkin lymphoma.
    Bailly C; Carlier T; Tessoulin B; Gastinne T; Kraeber-Bodere F; Le Gouill S; Bodet-Milin C
    Hematol Oncol; 2022 Oct; 40(4):796-800. PubMed ID: 35044695
    [No Abstract]   [Full Text] [Related]  

  • 26. Role of radiation in chimeric antigen receptor T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma: Current studies and future prospects.
    Yu L; Zou R; He J; Qu C
    Crit Rev Oncol Hematol; 2024 Jul; 199():104390. PubMed ID: 38782146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy.
    Guidetti A; Dodero A; Lorenzoni A; Pizzamiglio S; Argiroffi G; Chiappella A; Bagnoli F; Marasco V; Carniti C; Monfrini C; Seregni E; Pennisi M; Verderio P; Alessi A; Corradini P
    Cancer; 2023 Jan; 129(2):255-263. PubMed ID: 36385707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.
    Kiamanesh Z; Ayati N; Sadeghi R; Hawkes E; Lee ST; Scott AM
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4661-4676. PubMed ID: 35932329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric Antigen Receptor T-Cell Therapy of Neurolymphomatosis Monitored by FDG PET/CT.
    Li S; Wang H; Wang G; Lu X; Yang J
    Clin Nucl Med; 2023 May; 48(5):445-447. PubMed ID: 36716490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy.
    Sjöholm T; Korenyushkin A; Gammelgård G; Sarén T; Lövgren T; Loskog A; Essand M; Kullberg J; Enblad G; Ahlström H
    Cancer Imaging; 2022 Dec; 22(1):76. PubMed ID: 36575477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic Imaging in B-Cell Lymphomas during CAR-T Cell Therapy.
    Linguanti F; Abenavoli EM; Berti V; Lopci E
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Splenic Pseudoprogression After CAR-T Therapy Detected by 18 F-FDG PET/CT in a Refractory Diffuse Large B-Cell Lymphoma Patient.
    Yao X; Wang H; Kan Y; Wang W; Yang J
    Clin Nucl Med; 2024 Aug; 49(8):784-786. PubMed ID: 38598485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview.
    Ferrari C; Maggialetti N; Masi T; Nappi AG; Santo G; Niccoli Asabella A; Rubini G
    J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33803667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy.
    Vercellino L; de Jong D; di Blasi R; Kanoun S; Reshef R; Schwartz LH; Dercle L
    Front Oncol; 2021; 11():664688. PubMed ID: 34123825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positron emission tomography/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: An update.
    Juweid ME; Mueller M; Alhouri A; A-Risheq MZ; Mottaghy FM
    Cancer; 2021 Oct; 127(20):3727-3741. PubMed ID: 34286864
    [No Abstract]   [Full Text] [Related]  

  • 37. Chimeric Antigen Receptor T-Cell Therapy and Imaging Applications for Large B-Cell Lymphoma.
    Mulholland N; Chandra J; Sanderson R; Kuhnl A
    Radiology; 2023 Jun; 307(5):e221362. PubMed ID: 37310248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baseline [
    Marchal E; Palard-Novello X; Lhomme F; Meyer ME; Manson G; Devillers A; Marolleau JP; Houot R; Girard A
    Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):481-489. PubMed ID: 37721580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
    Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
    Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lymphoma pseudoprogression observed on [18F]FDG PET-CT scan 15 days after CAR-T infusion.
    Cohen D; Beyar-Katz O; Even-Sapir E; Perry C
    Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2447-2449. PubMed ID: 35146579
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.